Trial Profile
Phase I/II Study of the Combination of Bendamustine, Rituximab and MK-2206 in the Treatment of Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs MK 2206 (Primary) ; Bendamustine; Rituximab
- Indications Chronic lymphocytic leukaemia; Lymphoid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2017 Results published in the American Journal of Hematology
- 20 May 2016 Status changed from active, no longer recruiting to completed.
- 16 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.